Breast Cancer Breakthroughs Reported In Oncotarget

Oncotarget is known for being one of the most innovative journals in the biomedical community. Publishing twice each week, Oncotarget brings the most recent, cutting-edge work in the field of oncology to the attention of the whole medical community.

Oncology is one of the most research-intensive fields within all of medicine. Cancer touches almost every individual. Everyone has a family member, co-worker or friend who has been impacted by this terrible disease. Oncologists study and treat cancer. They are constantly on the lookout for any improvements available for their patients. Learn more about Oncotarget at researchgate.net

On November 15, 2017, Oncotarget broke news that an aggressive type of breast cancer cell responds to hormone therapy. This is great news for women with the fastest spreading and most dangerous forms of this disease.

Oncotarget was proud to go to publication with this important news featured on the cover. The research was conducted at the famed Mayo Clinic. The team there found that since these aggressive cancer cells lack a type of estrogen receptor. Although it is still early, this finding opens up potential pathways for research in animal models, and eventually in humans.

Recently, Oncotarget has also been able to award grants to four researchers from around the world. They include scholars at the University of Torino in Italy, the National Institute of Immunology in India and Aligarh Muslim University, also in India. Follow Oncotarget on Linkedin.

These grants took the form of travel sponsorship. Oncotarget’s sponsorship allowed these researchers to present their innovative work at the Frontiers in Cancer Science 2017 conference in Singapore. Oncotarget is committed to aiding the spread of knowledge to facilitate advances in cancer treatment. They continue to foster advances and the march towards a cure, both through publishing research and making live presentations possible.

Learn more: https://www.ncbi.nlm.nih.gov/pmc/journals/1558/

Leave a Reply

Your email address will not be published. Required fields are marked *